Previous 10 | Next 10 |
WAYNE, Pa., July 03, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of directors, effective July 2, 2019. ...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Gainers: Cemtrex (NASDAQ: CETX ) +120% . The Howard Hughes (NYSE: HHC ) +38% . J.Jill (NYSE: JILL ) +21% . Foresight Autonomous Holdings (NASDAQ: FRSX ) +21% . Zogenix (NASDAQ: ZGNX ) +21% . Herman Miller (NASDAQ: MLHR ) +18% . Atossa Genetics (NASDAQ: ATOS ) +16% . Dova...
XpresSpa Group (NASDAQ: XSPA ) -53% . More news on: XpresSpa Group, Inc., Aclaris Therapeutics, Inc., Pier 1 Imports, Inc., Stocks on the move, Read more ...
Glancy Prongay & Murray LLP (“GPM”) announces the continuation of its investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors concerning the Company and its officers’ possible violations...
Aclaris Therapeutics (NASDAQ: ACRS ) is set for a significant down move on the heels of a failed Phase 2 clinical trial evaluating ATI-502 in patients with an autoimmune disorder characterized by hair loss called alopecia areata. More news on: Aclaris Therapeutics, Inc., Healthcare stock...
ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company fo...
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors concerning the Company and its officers’ possible violations of federal securitie...
An Aclaris ( ACRS -2.2% ) advertisement for its Eskata hydrogen peroxide topical solution "makes false or misleading claims " about the product's risks and efficacy, the Food and Drug Administration says. More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the mo...
WAYNE, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an i...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...